{"id":80968,"date":"2026-06-10T08:50:53","date_gmt":"2026-06-10T03:20:53","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2026\/06\/10\/correction-from-source-entheon-biomedical-corp-issues-correction-to-news-release-dated-june-9-2026\/"},"modified":"2026-06-10T08:50:53","modified_gmt":"2026-06-10T03:20:53","slug":"correction-from-source-entheon-biomedical-corp-issues-correction-to-news-release-dated-june-9-2026","status":"publish","type":"post","link":"https:\/\/new.matribhumisamachar.com\/en\/2026\/06\/10\/correction-from-source-entheon-biomedical-corp-issues-correction-to-news-release-dated-june-9-2026\/","title":{"rendered":"CORRECTION FROM SOURCE: Entheon Biomedical Corp. Issues Correction to News Release Dated June 9, 2026"},"content":{"rendered":"

<\/p>\n

Vancouver, British Columbia–(Newsfile Corp. – June 9, 2026) – Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) (“Entheon<\/b>” or the “Company<\/b>“) wishes to correct the effective date of the appointment of Adam Emes as a director of the Company as stated in the Company’s news release dated June 9, 2026. The appointment of Mr. Emes to the Company’s Board of Directors is effective June 9, 2026, not April 3, 2025 as previously stated. All other information contained in the news release dated June 9, 2026 remains unchanged.<\/p>\n

About Entheon Biomedical Corp.<\/b>
\nEntheon is a biotechnology research and development company interested in treating addiction and substance use disorders.<\/p>\n

On Behalf of the Board of Directors,<\/b>
\nTimothy Ko, CEO and Director<\/p>\n

\n

For more information, please contact the Company at:
\nEntheon Biomedical Corp.
\nTimothy Ko, CEO
\n1 (604) 562-3932
\ntimothy@entheonbiomedical.com<\/a>
\nhttps:\/\/entheonbiomedical.com<\/a><\/p>\n<\/div>\n

To view the source version of this press release, please visit https:\/\/www.newsfilecorp.com\/release\/300836<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Vancouver, British Columbia–(Newsfile Corp. – June 9, 2026) – Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) (“Entheon” or the “Company“) wishes to correct the effective date of the appointment of Adam Emes as a director of the Company as stated in the Company’s news release dated June 9, 2026. The appointment of Mr. […]<\/p>\n","protected":false},"author":12,"featured_media":106422,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[54732],"tags":[],"class_list":["post-80968","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases"],"_links":{"self":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/80968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=80968"}],"version-history":[{"count":0,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/80968\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media\/106422"}],"wp:attachment":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=80968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=80968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=80968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}